Cited by 102Gene expression and cancer classificationBreast Cancer Treatment StudiesBioinformatics and Genomic Networks

Group lasso regularized deep learning for cancer prognosis from multi-omics and clinical features

Open access
Xie, Gangcai, Dong, Chengliang, Kong, Yinfei, Zhong, Jiang F., Li, Mingyao, Wang, Kai·2019·Genes

Abstract

Accurate prognosis of patients with cancer is important for the stratification of patients, the optimization of treatment strategies, and the design of clinical trials. Both clinical features and molecular data can be used for this purpose, for instance, to predict the survival of patients censored at specific time points. Multi-omics data, including genome-wide gene expression, methylation, protein expression, copy number alteration, and somatic mutation data, are becoming increasingly common in cancer studies. To harness the rich information in multi-omics data, we developed GDP (Group lass regularized Deep learning for cancer Prognosis), a computational tool for survival prediction using both clinical and multi-omics data. GDP integrated a deep learning framework and Cox proportional hazard model (CPH) together, and applied group lasso regularization to incorporate gene-level group prior knowledge into the model training process. We evaluated its performance in both simulated and real data from The Cancer Genome Atlas (TCGA) project. In simulated data, our results supported the importance of group prior information in the regularization of the model. Compared to the standard lasso regularization, we showed that group lasso achieved higher prediction accuracy when the group prior knowledge was provided. We also found that GDP performed better than CPH for complex survival data. Furthermore, analysis on real data demonstrated that GDP performed favorably against other methods in several cancers with large-scale omics data sets, such as glioblastoma multiforme, kidney renal clear cell carcinoma, and bladder urothelial carcinoma. In summary, we demonstrated that GDP is a powerful tool for prognosis of patients with cancer, especially when large-scale molecular features are available.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/genes10030240

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [25]Martín Abadi A.A. Paul B. Brevdo E. Zhifeng C. Craig C. Greg S. Corrado A.D. Jeffrey D. Devin M. Sanjay G. Google research: TensorFlow: Large-scale machine learning on heterogeneous distributed systems arXiv 2016 1603.04467

Cited by

Sorted by citations

Authors
Xie, G., Dong, C., Kong, Y., Zhong, J. F., Li, M., & Wang, K.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • California State University, Fullerton (US)
  • University of Southern California (US)
  • University of Pennsylvania (US)
Corresponding author
Wang, Kai
Venue
Genes
Publisher
MDPI AG
Published
2019-03-21
Volume
10
Issue
3
Pages
240
ISSN
2073-4425 (ISSN-L)
OpenAlex
W2922815614
Cited by
102
References
39
Citations by year
2026: 6 · 2025: 13 · 2024: 26 · 2023: 23 · 2022: 5 · 2021: 15 · 2020: 13 · 2019: 1
FWCI
2.81
Type
journal article
Language
en
Open access
Locations
  • Genes (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Children's Hospital of Philadelphia (NA)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
cancer prognosis, multi-omics data, group lasso regularization, Cox proportional hazards model, survival prediction, gene expression, DNA methylation, protein expression, copy number alterations, somatic mutations, clinical features, glioblastoma, clear cell renal cell carcinoma, bladder urothelial carcinoma, TCGA
MeSH terms
Deep Learning, Humans, Neoplasms, Prognosis, DNA Methylation, Computational Biology, Gene Expression Profiling, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review